NCT00828542View on ClinicalTrials.gov

Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
BreastfeedingContraception
Interventions
DRUG

etonogestrel implant

Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)

DRUG

depot medroxyprogesterone acetate

150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery

Trial Locations (1)

14049-900

University of Sao Paulo, Ribeirão Preto

All Listed Sponsors
lead

University of Sao Paulo

OTHER

NCT00828542 - Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women | Biotech Hunter | Biotech Hunter